News for Bolt Biotherapeutics, Inc. (BOLT)

Trading for Bolt Biotherapeutics (BOLT) Inc. has been temporarily suspended as the market awaits forthcoming announcements from the company. The halt in trading

In recent developments, analyst Stephen Willey from Stifel has adjusted the price target for Bolt Biotherapeutics (BOLT). The price target has been lowered from

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profi

In the first quarter, BOLT reported revenue of $1.22 million, surpassing the expected $768,000. Additionally, as of March 31, BOLT holds a cash reserve of $58.0

Revenue: $1.2 million for Q1 2025, surpassing the estimated $0.77 million.Earnings Per Share (EPS): Reported at -$0.29, better than the estimated -$0.36.Cash P

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of 14.71% and 19.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics (BOLT) recently showcased promising preclinical findings for its innovative Boltbody ISACs targeting CEACAM5 and PD-L1. These results were

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity,

**media[576536]**

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with

Bolt Biotherapeutics (BOLT) Q4 report: GAAP EPS misses by $0.04. $70.2M cash expected to fund operations & milestones through mid-2026.

PR NewswireMORRISTOWN, N.J., Feb. 18, 2025 Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New PipelineMORRISTOWN, N.J., Feb.

**media[538110]**

Bolt Biotherapeutics stock hits 52-week low at $0.54

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -11.11% and 12.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[459387]**

Bolt Biotherapeutics stock hits 52-week low at $0.65

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm ...

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt...